Share

December 2014; 1 (4) ArticleOpen Access

Rituximab as a first-line preventive treatment in pediatric NMOSDs

Preliminary results in 5 children

Giulia Longoni, Brenda Banwell, Massimo Filippi, E. Ann Yeh
First published December 11, 2014, DOI: https://doi.org/10.1212/NXI.0000000000000046
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1641

Share

Article Information

vol. 1 no. 4 e46
DOI: 
https://doi.org/10.1212/NXI.0000000000000046
PubMed: 
25520954
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received May 2, 2014
  • Accepted in final form October 13, 2014
  • First Published December 11, 2014.
Copyright & Usage: 
© 2014 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Giulia Longoni, MD,
    2. Brenda Banwell, MD,
    3. Massimo Filippi, MD and
    4. E. Ann Yeh, MD
  1. Giulia Longoni, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Brenda Banwell, MD,
    3. Scientific Advisory Boards:

    1. Scientific Advisory Board, Biogen-IDEC, Sanofi, Eli Lilly, Novartis.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. I have received speaker' s honoraria or travel support to speak at sponsored meetings from Biogen-IDEC, Merck- Serono, Teva Neuroscience and Bayer. I have not received this for more than 2 years.

    Editorial Boards:

    1. I serve on the Editorial Board for Neurology. I receive no financial remuneration. I also serve on the Editorial Board for a new journal, Multiple Sclerosis and Related Disorders. I receive compensation for this work.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I have served as a consultant to Biogen-IDEC, Eli Lilly, Sanofi.

    Speakers' Bureaus:

    1. I have spoken at an event supported by the Consortium of MS Centers

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Canadian Institutes of Health Research

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Multiple Sclerosis Society of Canada Multiple Sclerosis Scientific Research Foundation National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Massimo Filippi, MD and
    4. Scientific Advisory Boards:

    1. TEVA

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Bayer-Schering, Biogen-Idec, Merck-Serono, Teva

    Editorial Boards:

    1. Editor in CHief, Journal of Neurology. Editorial Board Member: AJNR, BMC Musculoskeletal Disorders, Clinical Neurology and Neurosurgery, Erciyes Medical Journal, Journal of Alzheimer' s Disease, Journal of Neuroimaging, Journal of Neurovirology, Lancet Neurology, Magnetic Resonance Imaging, Multiple Sclerosis, Neurological Sciences

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultancies: Bayer-Schering, Biogen-Idec, Merck-Serono, Novartis, Teva

    Speakers' Bureaus:

    1. Bayer-Schering, Biogen-Idec, Merck-Serono, Teva.

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Commercial entity: Bayer-Schering 2) Commercial entity: Biogen-Idec 3) Commercial entity: Merck-Serono 4) Commercial entity: Novartis 5) Commercial entity: Teva

    Research Support, Government Entities:

    1. 1) Italian Ministry of Health; grant number: RF-2010- 2313220; role: P.I.; duration: December 2012-November 2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) Fondazione Italiana Sclerosi Multipla (FISM) 2) CurePSP 3) the Gossweiler Foudation (Switzerland)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. E. Ann Yeh, MD
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology, editorial advisory board, 2013-present.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1) CIHR, Co-I. PI: Pohl 2) PCORI, Co-I, CE-1304-7079

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) National MS Society HC 0148 2) National MS Society PP2256 3) MS Society (Canada) 4) Dairy Farmers of Ontario 5) SickKids Innovation Fund

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Neuroimaging Research Unit, Institute of Experimental Neurology, and Department of Neurology, Division of Neuroscience (G.L., M.F.), San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; Department of Pediatrics (G.L., E.A.Y.), University of Toronto, and Division of Neurology (G.L., E.A.Y.), The Hospital for Sick Children, Toronto, Ontario, Canada; and Division of Neurology (B.B.), Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA.
  1. Correspondence to Dr. Yeh: ann.yeh{at}sickkids.ca

Article usage

Article usage: December 2014 to November 2023

AbstractFullPdfSource
Dec 2014356598117Highwire
Jan 201516046342Highwire
Jan 201509652pmc
Feb 20158217730Highwire
Feb 201507447pmc
Mar 201568569Highwire
Mar 201505126pmc
Apr 2015474212Highwire
Apr 201505448pmc
May 201539166Highwire
May 201504531pmc
Jun 2015292716Highwire
Jun 201503523pmc
Jul 2015452715Highwire
Jul 201504922pmc
Aug 2015551714Highwire
Aug 201503319pmc
Sep 201524136Highwire
Sep 201503719pmc
Oct 2015211614Highwire
Oct 201503813pmc
Nov 201522215Highwire
Nov 20150327pmc
Dec 2015192513Highwire
Dec 201503012pmc
Jan 201643247Highwire
Jan 201603116pmc
Feb 2016273110Highwire
Feb 201602115pmc
Mar 20162385Highwire
Mar 201602010pmc
Apr 201631128Highwire
Apr 20160198pmc
May 2016251712Highwire
May 201602414pmc
Jun 201631124Highwire
Jun 20160179pmc
Jul 20161985Highwire
Jul 20160219pmc
Aug 201632209Highwire
Aug 201603315pmc
Sep 20161164Highwire
Sep 20160169pmc
Oct 201638616Highwire
Oct 20160167pmc
Nov 201627119Highwire
Nov 20160188pmc
Dec 201629115Highwire
Dec 20160197pmc
Jan 2017521511Highwire
Jan 20170225pmc
Feb 201726510Highwire
Feb 201702015pmc
Mar 201725188Highwire
Mar 20170196pmc
Apr 20171895Highwire
Apr 201731111pmc
May 20171396Highwire
May 2017133pmc
Jun 20173172Highwire
Jun 201721213pmc
Jul 2017566Highwire
Jul 201731010pmc
Aug 2017824Highwire
Aug 201761414pmc
Sep 2017714Highwire
Sep 201731313pmc
Oct 20171021Highwire
Oct 2017477pmc
Nov 2017763Highwire
Nov 2017077pmc
Dec 20170155Highwire
Jan 20180140Highwire
Feb 20180162Highwire
Mar 2018293Highwire
Apr 20181181Highwire
Apr 2018278pmc
May 20180142Highwire
Jun 20181168Highwire
Jun 2018376pmc
Jul 20181202Highwire
Aug 201812510Highwire
Aug 201831214pmc
Sep 20181196Highwire
Oct 20180293Highwire
Nov 20181362Highwire
Dec 20180782Highwire
Jan 20191482Highwire
Feb 20195595Highwire
Mar 20193287Highwire
Apr 20193277Highwire
May 201931812Highwire
Jun 20192118Highwire
Jul 201911317Highwire
Aug 201941120Highwire
Sep 2019157Highwire
Oct 201952012Highwire
Nov 20192810Highwire
Dec 20190129Highwire
Jan 20201217Highwire
Feb 20200209Highwire
Mar 2020059Highwire
Apr 202051825Highwire
May 20200229Highwire
Jun 2020179Highwire
Jul 20203146Highwire
Aug 20200254Highwire
Sep 202041937Highwire
Oct 202032312Highwire
Nov 202051213Highwire
Dec 20202223Highwire
Jan 202141811Highwire
Feb 2021358Highwire
Mar 20214106Highwire
Apr 202182110Highwire
May 20214373Highwire
Jun 20213234Highwire
Jul 20213912Highwire
Aug 20213153Highwire
Sep 20213125Highwire
Oct 202121722Highwire
Nov 202112212Highwire
Dec 20212248Highwire
Jan 202201311Highwire
Feb 20225168Highwire
Mar 20225237Highwire
Apr 20222135Highwire
May 202211010Highwire
Jun 20225198Highwire
Jul 20221224Highwire
Aug 20226365Highwire
Sep 202264014Highwire
Oct 202253212Highwire
Nov 202286821Highwire
Dec 20224238Highwire
Jan 202364516Highwire
Feb 202342410Highwire
Mar 202322210Highwire
Apr 20238265Highwire
May 202342110Highwire
Jun 2023185Highwire
Jul 202321511Highwire
Aug 20232116Highwire
Sep 20231236Highwire
Oct 20231253Highwire
Nov 20230146Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me

Recommended articles